Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer (RPOS+2)
Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer : Faisability and Toxicity Study
Sponsor: Centre Antoine Lacassagne
A PHASE2 clinical study on Localized Breast Cancer, this trial is actively recruiting participants. The trial is conducted by Centre Antoine Lacassagne and has accumulated 9 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Feb 2025 — Feb 2026 [monthly]
Recruiting PHASE2
Phase: NA → PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Dec 2023 — Jul 2024 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Sep 2022 — Dec 2023 [monthly]
Recruiting NA
-
Sep 2021 — Sep 2022 [monthly]
Recruiting NA
-
Jun 2021 — Sep 2021 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Antoine Lacassagne
For direct contact, visit the study record on ClinicalTrials.gov .